News | May 29, 2007

Doctor Technique a Possible Factor in DES-Related Thrombosis

May 30, 2007 -- As concern and investigation continue concerning the link between drug-eluting stents and late-stent thrombosis, focus is now turning to the issue of improperly implanted stents by physicians. "The Wall Street Journal" reports this week that cardiologists' overconfidence in the benefits of drug-coated stents may have contributed to sloppy technique.

A recent study sponsored by a stent maker, states the Journal, found that two-thirds of the stents were implanted incorrectly.

In response, the Cardiovascular Research Foundation, a prominent advocate of stent technology, is launching an 11,000-patient study that is designed in part to examine whether less-than-optimal deployment of a stent is linked to the type of clots at the center of the debate, those that occur more than a year after implantation.

"We went through a period with drug-eluting stents thinking that it might not be so important to put them in perfectly," says Kirk Garratt, cardiologist at Lenox Hill Hospital, New York. "There was so much optimism and confidence about the stents that people might have gotten a little lazy," he says. Dr. Garratt and the other cardiologists quoted in this article consult for or get research-grant support or speaking fees from companies that make products used in stent procedures; in some cases, grants or fees are paid to the institution and not directly to the doctor.

The clotting problem, known as very late thrombosis, is rare, occurring in probably less than 0.5 percent of the roughly one million stent procedures done in the U.S. each year. But it happens long after doctors have believed patients were out of such danger, and the result is often either death or a major heart attack. The chief remedy is to keep patients for at least a year on both aspirin and a second drug called Plavix to prevent clots. But cost and bleeding risks are among the drawbacks to that strategy.

The Journal adds that not all experts agree that physician technique is a big culprit, and that most believe very late thrombosis has multiple contributors. Gary Mintz, a cardiologist at Cardiovascular Research Foundation, says that over time, the body's healing process covers over the stent, as well as placement shortcomings. "The effect of poor technique diminishes as time gets longer from implantation," he says.

The complete Wall Street Journal article, dated May 29, is available at www.wsj.com, or contact the authors at: [email protected] and [email protected]

Related Content

Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Overlay Init